Mr. Jim Hutchens reports

IMAGIN MEDICAL RESEARCH STUDY BEGINS

Imagin Medical Inc., as a follow-up to the announcement dated Nov. 29, has released additional information concerning the research study using the i/Blue imaging system being conducted at the University of Rochester Medical Center.

As of today, initial subjects have been recruited and procedures are being co-ordinated with the lead investigator's surgical schedule. During the 10-subject research study, Imagin's development team will work with the surgical staff to evaluate outcomes and adjust system components as needed to optimize product performance. "We are excited to see the study under way and are fortunate to be working with the University of Rochester, one of the nation's leading academic medical centres, on this important step forward for Imagin," said Jim Hutchens, Imagin's president and chief executive officer.

Demonstrating feasibility of the technology and defining the parameters for success will be followed by thorough assessment and refinement of all components for technical and cost-efficiency. Progress will be reported as information becomes available. Imagin anticipates all 10 procedures will be completed within four months, with the study remaining open for an additional nine months for subject follow-up. All updates will be published by the University of Rochester on the government's Clinical Trials website according to the research study guidelines.

The purpose of the study is to validate previous bench testing results that showed the i/Blue imaging system technology will enable physicians to "see" the cancer in less than 15 minutes versus the full hour required by today's technology, as well as blend the white and florescence images into one, placing the cancer in context within the bladder.

About Imagin Medical Inc.

Imagin Medical is developing imaging solutions for the early detection of cancer during minimally invasive surgeries. The company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due to a greater than 50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

We seek Safe Harbor.